The prospects of HPV vaccination in cervical cancer prevention: results of a new independent trial
- PMID: 22586628
- DOI: 10.1158/2159-8290.CD-11-0229
The prospects of HPV vaccination in cervical cancer prevention: results of a new independent trial
Abstract
Herrero and colleagues show that in a phase III randomized trial in Guanacaste, Costa Rica, the use of a human papillomavirus type 16 (HPV16) and HPV18 ASO4-adjuvanted vaccine (Cervarix) resulted in complete efficacy against 12-month persistent HPV16 and HPV18 infections and partial protection against HPV31, 33, and 45 in HPV-naïve young women ages 18 to 25.
©2011 AACR.
Comment on
-
Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica.Cancer Discov. 2011 Oct;1(5):408-19. doi: 10.1158/2159-8290.CD-11-0131. Epub 2011 Sep 9. Cancer Discov. 2011. PMID: 22586631 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
